Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070264 | 1.00 | BCHE (0.58) | BCHEMEN1KMT2ACD274KDM4E | |
| SCHEMBL115985 | 0.91 | ABCB1 (0.56) | BCHE | |
| SCHEMBL118372 | 0.86 | PRMT5 (0.50) | BCHE | |
| SCHEMBL115988 | 0.86 | PRMT5 (0.50) | BCHE | |
| SCHEMBL1438054 | 0.85 | BCHE (0.55) | BCHE | |
| SCHEMBL324108 | 0.85 | BCHE (0.64) | BCHEMEN1KMT2A | |
| SCHEMBL10070262 | 0.81 | MEN1 (0.53) | BCHEMEN1KMT2ACD274 | |
| SCHEMBL2295540 | 0.80 | APLNR (0.51) | BCHEMEN1KMT2ACD274ALDH1A1 | |
| SCHEMBL2298148 | 0.80 | APLNR (0.51) | BCHEMEN1KMT2ACD274ALDH1A1 | |
| SCHEMBL27731741 | 0.80 | APLNR (0.51) | BCHEMEN1KMT2ACD274ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | BCHE 4506/4885MEN1 4664/4885KMT2A 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.